{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:34:33Z","timestamp":1793410473322,"version":"4.5.0"},"reference-count":114,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Alzheimer\u2019s Disease (AD), a progressive and irreversible neurodegenerative disorder, is\nthe most common form of dementia worldwide. Currently, there is no disease-modifying AD drug,\nand the development of effective treatments is made even harder by the highly selective nature of\nthe Blood-Brain Barrier (BBB) that allows the passage only of molecules with specific chemical--\nphysical properties. In this context, nanomedicine and its Nanoparticles (NPs) offer potential solutions\nto the challenge of AD therapy, in particular, the requirements for i) BBB crossing, ii) multitarget\ntherapy iii) enhancement of pharmacokinetics; and iv) more precise delivery. In addition, the\npossibility to optimize NP biophysical and biological (i.e. target-specific ligands) properties allows\nfor highly tailored delivery platforms. Preclinical studies have demonstrated that nanotherapeutics\nprovide superior pharmacokinetics and brain uptake than free drugs and, on the other hand, these\nare also able to mitigate the side-effects of the symptomatic treatments approved by the FDA.\nAmong the plethora of potential AD nanodrugs, multitarget nanotherapeutics are considered the\nmost promising strategy due to their ability to hit simultaneously multiple pathogenic factors,\nwhile nano-nutraceuticals are emerging as interesting tools in the treatment\/prevention of AD. This\nreview provides a comprehensive overview of nanomedicine in AD therapy, focusing on key optimization\nof NPs properties, most promising nanotherapeutics in preclinical studies and difficulties\nthat are limiting the efficient translation from bench to bedside.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201818666210910162750","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T09:25:45Z","timestamp":1631525145000},"page":"17-31","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and\nClinical Trials: Challenges, Promises and Limitations"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8125-7972","authenticated-orcid":true,"given":"Syed Nasir Abbas","family":"Bukhari","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Aljouf, Sakaka, 2014, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"Livingston G.","year":"2017","unstructured":"Livingston G.; Sommerlad A.; Orgeta V.; Costafreda S.G.; Huntley J.; Ames D.; Ballard C.; Banerjee S.; Burns A.; Cohen-Mansfield J.; Cooper C.; Fox N.; Gitlin L.N.; Howard R.; Kales H.C.; Larson E.B.; Ritchie K.; Rockwood K.; Sampson E.L.; Samus Q.; Schneider L.S.; Selb\u00e6k G.; Teri L.; Mukadam N.; Dementia prevention, intervention, and care. Lancet 2017,390(10113),2673-2734","journal-title":"Lancet"},{"key":"ref=2","first-page":"1","year":"2019","unstructured":"World Alzheimer Report 2019 Attitudes to dementia. Alzheimer's Disease International 2019,1-166","journal-title":"Alzheimer's Disease International"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","volume":"5","author":"Hippius H.","year":"2003","unstructured":"Hippius H.; Neund\u00f6rfer G.; The discovery of Alzheimer\u2019s disease. Dialogues Clin Neurosci 2003,5(1),101-108","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.2147\/IJN.S231480","volume":"15","author":"Binda A.","year":"2020","unstructured":"Binda A.; Murano C.; Rivolta I.; Innovative therapies and nanomedicine applications for the treatment of alzheimer\u2019s disease: a state-of-the-art (2017-2020). Int J Nanomedicine 2020,15,6113-6135","journal-title":"Int J Nanomedicine"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"Briggs R.","year":"2016","unstructured":"Briggs R.; Kennelly S.P.; O\u2019Neill D.; Drug treatments in Alzheimer\u2019s disease. Clin Med (Lond) 2016,16(3),247-253","journal-title":"Clin Med (Lond)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"eabc7031","DOI":"10.1126\/sciadv.abc7031","volume":"6","author":"Zhou Y.","year":"2020","unstructured":"Zhou Y.; Zhu F.; Liu Y.; Zheng M.; Wang Y.; Zhang D.; Anraku Y.; Zou Y.; Li J.; Wu H.; Pang X.; Tao W.; Shimoni O.; Bush A.I.; Xue X.; Shi B.; Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy. Sci Adv 2020,6(41),eabc7031","journal-title":"Sci Adv"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/bs.pbr.2019.03.001","volume":"245","author":"Tosi G.","year":"2019","unstructured":"Tosi G.; Pederzoli F.; Belletti D.; Vandelli M.A.; Forni F.; Duskey J.T.; Ruozi B.; Nanomedicine in Alzheimer\u2019s disease: Amyloid beta targeting strategy. Prog Brain Res 2019,245,57-88","journal-title":"Prog Brain Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1039\/D0BM00756K","volume":"8","author":"Qian C.","year":"2020","unstructured":"Qian C.; Yuan C.; Li C.; Liu H.; Wang X.; Multifunctional nano-enabled delivery systems in Alzheimer\u2019s disease management. Biomater Sci 2020,8(20),5538-5554","journal-title":"Biomater Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/nn.4017","volume":"18","author":"Herrup K.","year":"2015","unstructured":"Herrup K.; The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 2015,18(6),794-799","journal-title":"Nat Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.arcmed.2010.03.007","volume":"41","author":"Maccioni R.B.","year":"2010","unstructured":"Maccioni R.B.; Far\u00edas G.; Morales I.; Navarrete L.; The revitalized tau hypothesis on Alzheimer\u2019s disease. Arch Med Res 2010,41(3),226-231","journal-title":"Arch Med Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","volume":"221","author":"Contestabile A.","year":"2011","unstructured":"Contestabile A.; The history of the cholinergic hypothesis. Behav Brain Res 2011,221(2),334-340","journal-title":"Behav Brain Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/jphp.13132","volume":"71","author":"Harilal S.","year":"2019","unstructured":"Harilal S.; Jose J.; Parambi D.G.T.; Kumar R.; Mathew G.E.; Uddin M.S.; Kim H.; Mathew B.; Advancements in nanotherapeutics for Alzheimer\u2019s disease: current perspectives. J Pharm Pharmacol 2019,71(9),1370-1383","journal-title":"J Pharm Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/aje\/kwn229","volume":"168","author":"Beydoun M.A.","year":"2008","unstructured":"Beydoun M.A.; Lhotsky A.; Wang Y.; Dal Forno G.; An Y.; Metter E.J.; Ferrucci L.; O\u2019Brien R.; Zonderman A.B.; Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer\u2019s disease. Am J Epidemiol 2008,168(10),1179-1189","journal-title":"Am J Epidemiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"107286","DOI":"10.1155\/2009\/107286","volume":"2009","author":"D\u00edaz-Ruiz C.","year":"2009","unstructured":"D\u00edaz-Ruiz C.; Wang J.; Ksiezak-Reding H.; Ho L.; Qian X.; Humala N.; Thomas S.; Mart\u00ednez-Mart\u00edn P.; Pasinetti G.M.; Role of hypertension in aggravating abeta neuropathology of ad type and tau-mediated motor impairment. Cardiovasc Psychiatry Neurol 2009,2009,107286","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/IJN.S200490","volume":"14","author":"Tiwari S.","year":"2019","unstructured":"Tiwari S.; Atluri V.; Kaushik A.; Yndart A.; Nair M.; Alzheimer\u2019s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 2019,14,5541-5554","journal-title":"Int J Nanomedicine"},{"key":"ref=16","first-page":"2020","year":"2020","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2020,2020","journal-title":"Alzheimers Dement"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"Vaz M.","year":"2020","unstructured":"Vaz M.; Silvestre S.; Alzheimer\u2019s disease: Recent treatment strategies. Eur J Pharmacol 2020,887,173554","journal-title":"Eur J Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.4155\/fmc-2016-0103","volume":"8","author":"Santos M.A.","year":"2016","unstructured":"Santos M.A.; Chand K.; Chaves S.; Recent progress in repositioning Alzheimer\u2019s disease drugs based on a multitarget strategy. Future Med Chem 2016,8(17),2113-2142","journal-title":"Future Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.4103\/1673-5374.165313","volume":"10","author":"Moreno S.","year":"2015","unstructured":"Moreno S.; Cer\u00f9 M.P.; In search for novel strategies towards neuroprotection and neuroregeneration: is PPAR\u03b1 a promising therapeutic target? Neural Regen Res 2015,10(9),1409-1412","journal-title":"Neural Regen Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jconrel.2014.03.054","volume":"190","author":"Park K.","year":"2014","unstructured":"Park K.; Controlled drug delivery systems: past forward and future back. J Control Release 2014,190,3-8","journal-title":"J Control Release"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"Hardy J.A.","year":"1992","unstructured":"Hardy J.A.; Higgins G.A.; Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 1992,256(5054),184-185","journal-title":"Science"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/humu.22117","volume":"33","author":"Cruts M.","year":"2012","unstructured":"Cruts M.; Theuns J.; Van Broeckhoven C.; Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012,33(9),1340-1344","journal-title":"Hum Mutat"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41467-020-16074-2","volume":"11","author":"Calvo-Rodriguez M.","year":"2020","unstructured":"Calvo-Rodriguez M.; Hou S.S.; Snyder A.C.; Kharitonova E.K.; Russ A.N.; Das S.; Fan Z.; Muzikansky A.; Garcia-Alloza M.; Serrano-Pozo A.; Hudry E.; Bacskai B.J.; Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer\u2019s disease. Nat Commun 2020,11(1),2146","journal-title":"Nat Commun"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/jnc.13632","volume":"139","author":"Karran E.","year":"2016","unstructured":"Karran E.; De Strooper B.; The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem 2016,139(Suppl. 2),237-252","journal-title":"J Neurochem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"Gauthier S.","year":"2016","unstructured":"Gauthier S.; Feldman H.H.; Schneider L.S.; Wilcock G.K.; Frisoni G.B.; Hardlund J.H.; Moebius H.J.; Bentham P.; Kook K.A.; Wischik D.J.; Schelter B.O.; Davis C.S.; Staff R.T.; Bracoud L.; Shamsi K.; Storey J.M.; Harrington C.R.; Wischik C.M.; Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 2016,388(10062),2873-2884","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1196\/annals.1427.010","volume":"1147","author":"Pratic\u00f2 D.","year":"2008","unstructured":"Pratic\u00f2 D.; Evidence of oxidative stress in Alzheimer\u2019s disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 2008,1147,70-78","journal-title":"Ann N Y Acad Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3389\/fnins.2019.01444","volume":"13","author":"Llanos-Gonz\u00e1lez E.","year":"2020","unstructured":"Llanos-Gonz\u00e1lez E.; Henares-Chavarino \u00c1.A.; Pedrero-Prieto C.M.; Garc\u00eda-Carpintero S.; Fronti\u00f1&#xE1;n-Rubio J.; Sancho-Bielsa F.J.; Alcain F.J.; Peinado J.R.; Rabanal-Ru\u00edz Y.; Dur\u00e1n-Prado M.; Interplay between mitochondrial oxidative disorders and proteostasis in alzheimer\u2019s disease. Front Neurosci 2020,13,1444","journal-title":"Front Neurosci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.mehy.2003.12.045","volume":"63","author":"Swerdlow R.H.","year":"2004","unstructured":"Swerdlow R.H.; Khan S.M.; A \u201cmitochondrial cascade hypothesis\u201d for sporadic Alzheimer\u2019s disease. Med Hypotheses 2004,63(1),8-20","journal-title":"Med Hypotheses"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"Heneka M.T.","year":"2015","unstructured":"Heneka M.T.; Carson M.J.; El Khoury J.; Landreth G.E.; Brosseron F.; Feinstein D.L.; Jacobs A.H.; Wyss-Coray T.; Vitorica J.; Ransohoff R.M.; Herrup K.; Frautschy S.A.; Finsen B.; Brown G.C.; Verkhratsky A.; Yamanaka K.; Koistinaho J.; Latz E.; Halle A.; Petzold G.C.; Town T.; Morgan D.; Shinohara M.L.; Perry V.H.; Holmes C.; Bazan N.G.; Brooks D.J.; Hunot S.; Joseph B.; Deigendesch N.; Garaschuk O.; Boddeke E.; Dinarello C.A.; Breitner J.C.; Cole G.M.; Golenbock D.T.; Kummer M.P.; Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 2015,14(4),388-405","journal-title":"Lancet Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e1801362","DOI":"10.1002\/adma.201801362","volume":"30","author":"Furtado D.","year":"2018","unstructured":"Furtado D.; Bj\u00f6rnmalm M.; Ayton S.; Bush A.I.; Kempe K.; Caruso F.; Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater 2018,30(46),e1801362","journal-title":"Adv Mater"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuroscience.2005.06.017","volume":"138","author":"Henderson V.W.","year":"2006","unstructured":"Henderson V.W.; Estrogen-containing hormone therapy and Alzheimer\u2019s disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006,138(3),1031-1039","journal-title":"Neuroscience"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13195-015-0109-2","volume":"7","author":"Atri A.","year":"2015","unstructured":"Atri A.; Hendrix S.B.; Pejovi\u0107 V.; Hofbauer R.K.; Edwards J.; Molinuevo J.L.; Graham S.M.; Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer\u2019s dementia: a pooled area under the curve analysis. Alzheimers Res Ther 2015,7(1),28","journal-title":"Alzheimers Res Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e12050","DOI":"10.1002\/trc2.12050","volume":"6","author":"Cummings J.","year":"2020","unstructured":"Cummings J.; Lee G.; Ritter A.; Sabbagh M.; Zhong K.; Alzheimer\u2019s disease drug development pipeline: 2020. Alzheimers Dement (N Y) 2020,6(1),e12050","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.nano.2017.12.006","volume":"14","author":"Carradori D.","year":"2018","unstructured":"Carradori D.; Balducci C.; Re F.; Brambilla D.; Le Droumaguet B.; Flores O.; Gaudin A.; Mura S.; Forloni G.; Ordo\u00f1ez-Gutierrez L.; Wandosell F.; Masserini M.; Couvreur P.; Nicolas J.; Andrieux K.; Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer\u2019s disease-like transgenic mouse model. Nanomedicine 2018,14(2),609-618","journal-title":"Nanomedicine"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jconrel.2020.05.044","volume":"325","author":"Wilson B.","year":"2020","unstructured":"Wilson B.; Geetha K.M.; Neurotherapeutic applications of nanomedicine for treating Alzheimer\u2019s disease. J Control Release 2020,325,25-37","journal-title":"J Control Release"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"Anselmo A.C.","year":"2019","unstructured":"Anselmo A.C.; Mitragotri S.; Nanoparticles in the clinic: An update. Bioeng Transl Med 2019,4(3),e10143","journal-title":"Bioeng Transl Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0006-8993(95)00023-J","volume":"674","author":"Kreuter J.","year":"1995","unstructured":"Kreuter J.; Alyautdin R.N.; Kharkevich D.A.; Ivanov A.A.; Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995,674(1),171-174","journal-title":"Brain Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3762\/bjnano.11.72","volume":"11","author":"Lombardo S.M.","year":"2020","unstructured":"Lombardo S.M.; Schneider M.; T\u00fcreli A.E.; G\u00fcnday T\u00fcreli N.; Key for crossing the BBB with nanoparticles: the rational design. Beilstein J Nanotechnol 2020,11,866-883","journal-title":"Beilstein J Nanotechnol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"14265","DOI":"10.1073\/pnas.0805135105","volume":"105","author":"Lundqvist M.","year":"2008","unstructured":"Lundqvist M.; Stigler J.; Elia G.; Lynch I.; Cedervall T.; Dawson K.A.; Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008,105(38),14265-14270","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jconrel.2015.11.032","volume":"222","author":"Johnsen K.B.","year":"2016","unstructured":"Johnsen K.B.; Moos T.; Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes. J Control Release 2016,222,32-46","journal-title":"J Control Release"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"18220","DOI":"10.1038\/s41598-020-75253-9","volume":"10","author":"Ohta S.","year":"2020","unstructured":"Ohta S.; Kikuchi E.; Ishijima A.; Azuma T.; Sakuma I.; Ito T.; Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood-brain barrier opening. Sci Rep 2020,10(1),18220","journal-title":"Sci Rep"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1039\/c3nr05559k","volume":"6","author":"Pozzi D.","year":"2014","unstructured":"Pozzi D.; Colapicchioni V.; Caracciolo G.; Piovesana S.; Capriotti A.L.; Palchetti S.; De Grossi S.; Riccioli A.; Amenitsch H.; Lagan\u00e0 A.; Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 2014,6(5),2782-2792","journal-title":"Nanoscale"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13346-015-0218-2","volume":"5","author":"Cole J.T.","year":"2015","unstructured":"Cole J.T.; Holland N.B.; Multifunctional nanoparticles for use in theranostic applications. Drug Deliv Transl Res 2015,5(3),295-309","journal-title":"Drug Deliv Transl Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijpharm.2005.11.040","volume":"310","author":"Gao K.","year":"2006","unstructured":"Gao K.; Jiang X.; Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm 2006,310(1-2),213-219","journal-title":"Int J Pharm"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.ultrasmedbio.2016.01.019","volume":"42","author":"Shen Y.","year":"2016","unstructured":"Shen Y.; Guo J.; Chen G.; Chin C.T.; Chen X.; Chen J.; Wang F.; Chen S.; Dan G.; Delivery of liposomes with different sizes to mice brain after\u00a0sonication by focused ultrasound in the presence of\u00a0microbubbles. Ultrasound Med Biol 2016,42(7),1499-1511","journal-title":"Ultrasound Med Biol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","volume":"66","author":"Sonavane G.","year":"2008","unstructured":"Sonavane G.; Tomoda K.; Makino K.; Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008,66(2),274-280","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e10153","DOI":"10.1002\/btm2.10153","volume":"5","author":"Nowak M.","year":"2019","unstructured":"Nowak M.; Brown T.D.; Graham A.; Helgeson M.E.; Mitragotri S.; Size, shape, and flexibility influence nanoparticle transport across brain endothelium under flow. Bioeng Transl Med 2019,5(2),e10153","journal-title":"Bioeng Transl Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"9616","DOI":"10.1021\/ja404345s","volume":"135","author":"Liang H.","year":"2013","unstructured":"Liang H.; Rossouw D.; Zhao H.; Cushing S.K.; Shi H.; Korinek A.; Xu H.; Rosei F.; Wang W.; Wu N.; Botton G.A.; Ma D.; Asymmetric silver \u201cnanocarrot\u201d structures: solution synthesis and their asymmetric plasmonic resonances. J Am Chem Soc 2013,135(26),9616-9619","journal-title":"J Am Chem Soc"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2174\/1381612826666200311131658","volume":"26","author":"Bahadur S.","year":"2020","unstructured":"Bahadur S.; Sachan N.; Harwansh R.K.; Deshmukh R.; Nanoparticlized system: promising approach for the management of alzheimer\u2019s disease through intranasal delivery. Curr Pharm Des 2020,26(12),1331-1344","journal-title":"Curr Pharm Des"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jconrel.2019.10.034","volume":"314","author":"Hettiarachchi S.D.","year":"2019","unstructured":"Hettiarachchi S.D.; Zhou Y.; Seven E.; Lakshmana M.K.; Kaushik A.K.; Chand H.S.; Leblanc R.M.; Nanoparticle-mediated approaches for Alzheimer\u2019s disease pathogenesis, diagnosis, and therapeutics. J Control Release 2019,314,125-140","journal-title":"J Control Release"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"Allen T.M.","year":"2013","unstructured":"Allen T.M.; Cullis P.R.; Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013,65(1),36-48","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.2147\/IJN.S183117","volume":"13","author":"Ross C.","year":"2018","unstructured":"Ross C.; Taylor M.; Fullwood N.; Allsop D.; Liposome delivery systems for the treatment of Alzheimer\u2019s disease. Int J Nanomedicine 2018,13,8507-8522","journal-title":"Int J Nanomedicine"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnsyn.2020.00020","volume":"12","author":"Ord\u00f3&#xF1;ez-Guti\u00e9rrez L.","year":"2020","unstructured":"Ord\u00f3&#xF1;ez-Guti\u00e9rrez L.; Wandosell F.; Nanoliposomes as a therapeutic tool for alzheimer\u2019s disease. Front Synaptic Neurosci 2020,12,20","journal-title":"Front Synaptic Neurosci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1016\/j.biomaterials.2010.04.044","volume":"31","author":"Gobbi M.","year":"2010","unstructured":"Gobbi M.; Re F.; Canovi M.; Beeg M.; Gregori M.; Sesana S.; Sonnino S.; Brogioli D.; Musicanti C.; Gasco P.; Salmona M.; Masserini M.E.; Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 2010,31(25),6519-6529","journal-title":"Biomaterials"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ijpharm.2013.03.037","volume":"448","author":"Mufamadi M.S.","year":"2013","unstructured":"Mufamadi M.S.; Choonara Y.E.; Kumar P.; Modi G.; Naidoo D.; van Vuuren S.; Ndesendo V.M.; Toit L.C.; Iyuke S.E.; Pillay V.; Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int J Pharm 2013,448(1),267-281","journal-title":"Int J Pharm"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","volume":"452","author":"Yang Z.Z.","year":"2013","unstructured":"Yang Z.Z.; Zhang Y.Q.; Wang Z.Z.; Wu K.; Lou J.N.; Qi X.R.; Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm 2013,452(1-2),344-354","journal-title":"Int J Pharm"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/08982104.2020.1787440","volume":"31","author":"Salimi A.","year":"2020","unstructured":"Salimi A.; Gobadian H.; Sharif Makhmalzadeh B.; Dermal pharmacokinetics of rivastigmine-loaded liposomes: an ex vivo-in vivo correlation study. J Liposome Res 2020,31(3),246-254","journal-title":"J Liposome Res"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/DDDT.S113171","volume":"10","author":"Al Asmari A.K.","year":"2016","unstructured":"Al Asmari A.K.; Ullah Z.; Tariq M.; Fatani A.; Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther 2016,10,205-215","journal-title":"Drug Des Devel Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","volume":"23","author":"Misra S.","year":"2016","unstructured":"Misra S.; Chopra K.; Sinha V.R.; Medhi B.; Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv 2016,23(4),1434-1443","journal-title":"Drug Deliv"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jconrel.2015.10.006","volume":"219","author":"Hickey J.W.","year":"2015","unstructured":"Hickey J.W.; Santos J.L.; Williford J.M.; Mao H.Q.; Control of polymeric nanoparticle size to improve therapeutic delivery. J Control Release 2015,219,536-547","journal-title":"J Control Release"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/03639045.2012.758130","volume":"40","author":"Md S.","year":"2014","unstructured":"Md S.; Ali M.; Baboota S.; Sahni J.K.; Bhatnagar A.; Ali J.; Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm 2014,40(2),278-287","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00702-016-1527-4","volume":"124","author":"Baysal I.","year":"2017","unstructured":"Baysal I.; Ucar G.; Gultekinoglu M.; Ulubayram K.; Yabanoglu-Ciftci S.; Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J Neural Transm (Vienna) 2017,124(1),33-45","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","volume":"1200","author":"Wilson B.","year":"2008","unstructured":"Wilson B.; Samanta M.K.; Santhi K.; Kumar K.P.; Paramakrishnan N.; Suresh B.; Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\u2019s disease. Brain Res 2008,1200,159-168","journal-title":"Brain Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e1805730","DOI":"10.1002\/adma.201805730","volume":"31","author":"Yang G.","year":"2019","unstructured":"Yang G.; Phua S.Z.F.; Bindra A.K.; Zhao Y.; Degradability and clearance of inorganic nanoparticles for biomedical applications. Adv Mater 2019,31(10),e1805730","journal-title":"Adv Mater"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijbiomac.2019.02.156","volume":"130","author":"Gupta J.","year":"2019","unstructured":"Gupta J.; Fatima M.T.; Islam Z.; Khan R.H.; Uversky V.N.; Salahuddin P.; Nanoparticle formulations in the diagnosis and therapy of Alzheimer\u2019s disease. Int J Biol Macromol 2019,130,515-526","journal-title":"Int J Biol Macromol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"20894","DOI":"10.1039\/C8NR04506B","volume":"10","author":"John T.","year":"2018","unstructured":"John T.; Gladytz A.; Kubeil C.; Martin L.L.; Risselada H.J.; Abel B.; Impact of nanoparticles on amyloid peptide and protein aggregation: a review with a focus on gold nanoparticles. Nanoscale 2018,10(45),20894-20913","journal-title":"Nanoscale"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s12035-019-01780-w","volume":"57","author":"Dos Santos Tramontin N.","year":"2020","unstructured":"Dos Santos Tramontin N.; da Silva S.; Arruda R.; Ugioni K.S.; Canteiro P.B.; de Bem Silveira G.; Mendes C.; Silveira P.C.L.; Muller A.P.; Gold nanoparticles treatment reverses brain damage in alzheimer\u2019s disease model. Mol Neurobiol 2020,57(2),926-936","journal-title":"Mol Neurobiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1007\/s12035-016-0136-4","volume":"54","author":"Ali T.","year":"2017","unstructured":"Ali T.; Kim M.J.; Rehman S.U.; Ahmad A.; Kim M.O.; Anthocyanin-loaded peg-gold nanoparticles enhanced the neuroprotection of anthocyanins in an a\u03b2 mouse model of alzheimer\u2019s disease. Mol Neurobiol 2017,54(8),6490-6506","journal-title":"Mol Neurobiol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/03639045.2016.1275668","volume":"43","author":"Karimzadeh M.","year":"2017","unstructured":"Karimzadeh M.; Rashidi L.; Ganji F.; Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells. Drug Dev Ind Pharm 2017,43(4),628-636","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.actbio.2016.09.010","volume":"46","author":"Yang L.","year":"2016","unstructured":"Yang L.; Yin T.; Liu Y.; Sun J.; Zhou Y.; Liu J.; Gold nanoparticle-capped mesoporous silica-based HO-responsive controlled release system for Alzheimer\u2019s disease treatment. Acta Biomater 2016,46,177-190","journal-title":"Acta Biomater"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"E250","DOI":"10.3390\/pharmaceutics10040250","volume":"10","author":"Nigro A.","year":"2018","unstructured":"Nigro A.; Pellegrino M.; Greco M.; Comand\u00e8 A.; Sisci D.; Pasqua L.; Leggio A.; Morelli C.; Dealing with skin and blood-brain barriers: the unconventional challenges of mesoporous silica nanoparticles. Pharmaceutics 2018,10(4),E250","journal-title":"Pharmaceutics"},{"key":"ref=72","first-page":"1479","volume":"20","author":"Sharma K.","year":"2019","unstructured":"Sharma K.; Cholinesterase inhibitors as alzheimer\u2019s therapeutics (review). Mol Med Rep 2019,20(2),1479-1487","journal-title":"Mol Med Rep"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpba.2011.11.025","volume":"61","author":"Qian S.","year":"2012","unstructured":"Qian S.; Wo S.K.; Zuo Z.; Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats. J Pharm Biomed Anal 2012,61,57-63","journal-title":"J Pharm Biomed Anal"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"E84","DOI":"10.3390\/pharmaceutics11020084","volume":"11","author":"Bonferoni M.C.","year":"2019","unstructured":"Bonferoni M.C.; Rossi S.; Sandri G.; Ferrari F.; Gavini E.; Rassu G.; Giunchedi P.; Nanoemulsions for \u201cnose-to-brain\u201d drug delivery. Pharmaceutics 2019,11(2),E84","journal-title":"Pharmaceutics"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/08982104.2014.899369","volume":"24","author":"Corace G.","year":"2014","unstructured":"Corace G.; Angeloni C.; Malaguti M.; Hrelia S.; Stein P.C.; Brandl M.; Gotti R.; Luppi B.; Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res 2014,24(4),323-335","journal-title":"J Liposome Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1208\/s12249-020-01652-w","volume":"21","author":"Igart\u00faa D.E.","year":"2020","unstructured":"Igart\u00faa D.E.; Martinez C.S.; Del V Alonso S.; Prieto M.J.; Combined therapy for alzheimer\u2019s disease: tacrine and pamam dendrimers co-administration reduces the side effects of the drug without modifying its activity. AAPS PharmSciTech 2020,21(3),110","journal-title":"AAPS PharmSciTech"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1523\/JNEUROSCI.0284-14.2014","volume":"34","author":"Balducci C.","year":"2014","unstructured":"Balducci C.; Mancini S.; Minniti S.; La Vitola P.; Zotti M.; Sancini G.; Mauri M.; Cagnotto A.; Colombo L.; Fiordaliso F.; Grigoli E.; Salmona M.; Snellman A.; Haaparanta-Solin M.; Forloni G.; Masserini M.; Re F.; Multifunctional liposomes reduce brain \u03b2-amyloid burden and ameliorate memory impairment in Alzheimer\u2019s disease mouse models. J Neurosci 2014,34(42),14022-14031","journal-title":"J Neurosci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.nano.2013.12.001","volume":"10","author":"Bana L.","year":"2014","unstructured":"Bana L.; Minniti S.; Salvati E.; Sesana S.; Zambelli V.; Cagnotto A.; Orlando A.; Cazzaniga E.; Zwart R.; Scheper W.; Masserini M.; Re F.; Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect A\u03b2 aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease. Nanomedicine 2014,10(7),1583-1590","journal-title":"Nanomedicine"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00702-013-0992-2","volume":"120","author":"Baysal I.","year":"2013","unstructured":"Baysal I.; Yabanoglu-Ciftci S.; Tunc-Sarisozen Y.; Ulubayram K.; Ucar G.; Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils. J Neural Transm (Vienna) 2013,120(6),903-910","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1021\/acschemneuro.9b00343","volume":"10","author":"Krishna K.V.","year":"2019","unstructured":"Krishna K.V.; Wadhwa G.; Alexander A.; Kanojia N.; Saha R.N.; Kukreti R.; Singhvi G.; Dubey S.K.; Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS Chem Neurosci 2019,10(9),4124-4135","journal-title":"ACS Chem Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1021\/nn4058215","volume":"8","author":"Song Q.","year":"2014","unstructured":"Song Q.; Huang M.; Yao L.; Wang X.; Gu X.; Chen J.; Chen J.; Huang J.; Hu Q.; Kang T.; Rong Z.; Qi H.; Zheng G.; Chen H.; Gao X.; Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer\u2019s disease by accelerating the clearance of amyloid-beta. ACS Nano 2014,8(3),2345-2359","journal-title":"ACS Nano"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13543776.2021.1832463","volume":"31","author":"Rombouts F.","year":"2021","unstructured":"Rombouts F.; Kusakabe K.I.; Hsiao C.C.; Gijsen H.J.M.; Small- molecule BACE1 inhibitors: a patent literature review (2011 to 2020). Expert Opin Ther Pat 2021,31(1),25-52","journal-title":"Expert Opin Ther Pat"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1021\/nn402310c","volume":"7","author":"Choi I.","year":"2013","unstructured":"Choi I.; Lee L.P.; Rapid detection of A\u03b2 aggregation and inhibition by dual functions of gold nanoplasmic particles: catalytic activator and optical reporter. ACS Nano 2013,7(7),6268-6277","journal-title":"ACS Nano"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1021\/cn300196n","volume":"4","author":"Mahmoudi M.","year":"2013","unstructured":"Mahmoudi M.; Quinlan-Pluck F.; Monopoli M.P.; Sheibani S.; Vali H.; Dawson K.A.; Lynch I.; Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid \u03b2 protein fibrillation in solution. ACS Chem Neurosci 2013,4(3),475-485","journal-title":"ACS Chem Neurosci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.bpj.2011.09.046","volume":"101","author":"Li H.","year":"2011","unstructured":"Li H.; Luo Y.; Derreumaux P.; Wei G.; Carbon nanotube inhibits the formation of \u03b2-sheet-rich oligomers of the Alzheimer\u2019s amyloid-&#x3B2;(16-22) peptide. Biophys J 2011,101(9),2267-2276","journal-title":"Biophys J"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1477-3155-11-32","volume":"11","author":"Glat M.","year":"2013","unstructured":"Glat M.; Skaat H.; Menkes-Caspi N.; Margel S.; Stern E.A.; Age-dependent effects of microglial inhibition in vivo on Alzheimer\u2019s disease neuropathology using bioactive-conjugated iron oxide nanoparticles. J Nanobiotechnology 2013,11,32","journal-title":"J Nanobiotechnology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jphotobiol.2019.01.012","volume":"192","author":"Ghalandari B.","year":"2019","unstructured":"Ghalandari B.; Asadollahi K.; Shakerizadeh A.; Komeili A.; Riazi G.; Kamrava S.K.; Attaran N.; Microtubule network as a potential candidate for targeting by gold nanoparticle-assisted photothermal therapy. J Photochem Photobiol B 2019,192,131-140","journal-title":"J Photochem Photobiol B"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","volume":"4","author":"Sonawane S.K.","year":"2019","unstructured":"Sonawane S.K.; Ahmad A.; Chinnathambi S.; Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in alzheimer\u2019s disease. ACS Omega 2019,4(7),12833-12840","journal-title":"ACS Omega"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-020-00626-1","volume":"18","author":"Gao C.","year":"2020","unstructured":"Gao C.; Chu X.; Gong W.; Zheng J.; Xie X.; Wang Y.; Yang M.; Li Z.; Gao C.; Yang Y.; Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer\u2019s disease. J Nanobiotechnology 2020,18(1),71","journal-title":"J Nanobiotechnology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"81001","DOI":"10.18632\/oncotarget.20944","volume":"8","author":"Huang N.","year":"2017","unstructured":"Huang N.; Lu S.; Liu X.G.; Zhu J.; Wang Y.J.; Liu R.T.; PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering A\u03b2 generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer\u2019s disease mice. Oncotarget 2017,8(46),81001-81013","journal-title":"Oncotarget"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"21116","DOI":"10.1021\/acsami.7b03816","volume":"9","author":"Han Q.","year":"2017","unstructured":"Han Q.; Cai S.; Yang L.; Wang X.; Qi C.; Yang R.; Wang C.; Molybdenum disulfide nanoparticles as multifunctional inhibitors against alzheimer\u2019s disease. ACS Appl Mater Interfaces 2017,9(25),21116-21123","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.11.060","volume":"80","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; An S.; Li J.; Kuang Y.; He X.; Guo Y.; Ma H.; Zhang Y.; Ji B.; Jiang C.; Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer\u2019s disease mice. Biomaterials 2016,80,33-45","journal-title":"Biomaterials"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.1039\/D0NR04037A","volume":"12","author":"Burilova E.A.","year":"2020","unstructured":"Burilova E.A.; Pashirova T.N.; Zueva I.V.; Gibadullina E.M.; Lushchekina S.V.; Sapunova A.S.; Kayumova R.M.; Rogov A.M.; Evtjugin V.G.; Sudakov I.A.; Vyshtakalyuk A.B.; Voloshina A.D.; Bukharov S.V.; Burilov A.R.; Petrov K.A.; Zakharova L.Y.; Sinyashin O.G.; Bi-functional sterically hindered phenol lipid-based delivery systems as potential multi-target agents against Alzheimer\u2019s disease via an intranasal route. Nanoscale 2020,12(25),13757-13770","journal-title":"Nanoscale"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijbiomac.2019.09.098","volume":"142","author":"Gao F.","year":"2020","unstructured":"Gao F.; Zhao J.; Liu P.; Ji D.; Zhang L.; Zhang M.; Li Y.; Xiao Y.; Preparation and in vitro evaluation of multi-target-directed selenium-chondroitin sulfate nanoparticles in protecting against the Alzheimer\u2019s disease. Int J Biol Macromol 2020,142,265-276","journal-title":"Int J Biol Macromol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jcis.2017.06.083","volume":"505","author":"Sun D.","year":"2017","unstructured":"Sun D.; Zhang W.; Yu Q.; Chen X.; Xu M.; Zhou Y.; Liu J.; Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid \u03b2 aggregation for treating Alzheimer\u2019s disease. J Colloid Interface Sci 2017,505,1001-1010","journal-title":"J Colloid Interface Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"120011","DOI":"10.1016\/j.ijpharm.2020.120011","volume":"591","author":"Arduino I.","year":"2020","unstructured":"Arduino I.; Iacobazzi R.M.; Riganti C.; Lopedota A.A.; Perrone M.G.; Lopalco A.; Cutrignelli A.; Cantore M.; Laquintana V.; Franco M.; Colabufo N.A.; Luurtsema G.; Contino M.; Denora N.; Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer\u2019s disease. Int J Pharm 2020,591,120011","journal-title":"Int J Pharm"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fphar.2014.00147","volume":"5","author":"Mecocci P.","year":"2014","unstructured":"Mecocci P.; Tinarelli C.; Schulz R.J.; Polidori M.C.; Nutraceuticals in cognitive impairment and Alzheimer\u2019s disease. Front Pharmacol 2014,5,147","journal-title":"Front Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"105314","DOI":"10.1016\/j.ejps.2020.105314","volume":"148","author":"Pinheiro R.G.R.","year":"2020","unstructured":"Pinheiro R.G.R.; Granja A.; Loureiro J.A.; Pereira M.C.; Pinheiro M.; Neves A.R.; Reis S.; Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer\u2019s disease. Eur J Pharm Sci 2020,148,105314","journal-title":"Eur J Pharm Sci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.2147\/IJN.S208332","volume":"14","author":"Yavarpour-Bali H.","year":"2019","unstructured":"Yavarpour-Bali H.; Ghasemi-Kasman M.; Pirzadeh M.; Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders. Int J Nanomedicine 2019,14,4449-4460","journal-title":"Int J Nanomedicine"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1021\/nn405077y","volume":"8","author":"Tiwari S.K.","year":"2014","unstructured":"Tiwari S.K.; Agarwal S.; Seth B.; Yadav A.; Nair S.; Bhatnagar P.; Karmakar M.; Kumari M.; Chauhan L.K.; Patel D.K.; Srivastava V.; Singh D.; Gupta S.K.; Tripathi A.; Chaturvedi R.K.; Gupta K.C.; Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer\u2019s disease model via canonical Wnt\/&#x3B2;-catenin pathway. ACS Nano 2014,8(1),76-103","journal-title":"ACS Nano"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1208\/s12248-012-9444-4","volume":"15","author":"Cheng K.K.","year":"2013","unstructured":"Cheng K.K.; Yeung C.F.; Ho S.W.; Chow S.F.; Chow A.H.; Baum L.; Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer\u2019s disease Tg2576 mice. AAPS J 2013,15(2),324-336","journal-title":"AAPS J"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"E277","DOI":"10.3390\/molecules22020277","volume":"22","author":"Loureiro J.A.","year":"2017","unstructured":"Loureiro J.A.; Andrade S.; Duarte A.; Neves A.R.; Queiroz J.F.; Nunes C.; Sevin E.; Fenart L.; Gosselet F.; Coelho M.A.; Pereira M.C.; Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of alzheimer\u2019s disease. Molecules 2017,22(2),E277","journal-title":"Molecules"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3389\/fphar.2018.00790","volume":"9","author":"Hua S.","year":"2018","unstructured":"Hua S.; de Matos M.B.C.; Metselaar J.M.; Storm G.; Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol 2018,9,790","journal-title":"Front Pharmacol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1002\/cpph.57","volume":"84","author":"Mullane K.","year":"2019","unstructured":"Mullane K.; Williams M.; Preclinical models of alzheimer\u2019s disease: relevance and translational validity. Curr Protocols Pharmacol 2019,84(1),e57","journal-title":"Curr Protocols Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"E1855","DOI":"10.3390\/cancers11121855","volume":"11","author":"Salvioni L.","year":"2019","unstructured":"Salvioni L.; Rizzuto M.A.; Bertolini J.A.; Pandolfi L.; Colombo M.; Prosperi D.; Thirty years of cancer nanomedicine: success, frustration, and hope. Cancers (Basel) 2019,11(12),E1855","journal-title":"Cancers (Basel)"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"9664","DOI":"10.1038\/s41598-020-66572-y","volume":"10","author":"Tekie F.S.M.","year":"2020","unstructured":"Tekie F.S.M.; Hajiramezanali M.; Geramifar P.; Raoufi M.; Dinarvand R.; Soleimani M.; Atyabi F.; Controlling evolution of protein corona: a prosperous approach to improve chitosan-based nanoparticle biodistribution and half-life. Sci Rep 2020,10(1),9664","journal-title":"Sci Rep"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/pharmaceutics13010038","volume":"13","author":"Topal G.R.","year":"2020","unstructured":"Topal G.R.; M\u00e9sz\u00e1ros M.; Porkol\u00e1b G.; Szecsk\u00f3 A.; Polg\u00e1r T.F.; Sikl\u00f3s L.; Deli M.A.; Veszelka S.; Bozkir A.; ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood-brain barrier. Pharmaceutics 2020,13(1),38","journal-title":"Pharmaceutics"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"E227","DOI":"10.3390\/pharmaceutics12030227","volume":"12","author":"Nanaki S.G.","year":"2020","unstructured":"Nanaki S.G.; Spyrou K.; Bekiari C.; Veneti P.; Baroud T.N.; Karouta N.; Grivas I.; Papadopoulos G.C.; Gournis D.; Bikiaris D.N.; Hierarchical porous carbon-plla and plga hybrid nanoparticles for intranasal delivery of galantamine for alzheimer\u2019s disease therapy. Pharmaceutics 2020,12(3),E227","journal-title":"Pharmaceutics"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1567201815666181004094707","volume":"16","author":"Sunena","year":"2019","unstructured":"Sunena ; Singh S.K.; Mishra D.N.; Nose to brain delivery of galantamine loaded nanoparticles: in-vivo pharmacodynamic and biochemical study in mice. Curr Drug Deliv 2019,16(1),51-58","journal-title":"Curr Drug Deliv"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1021\/acschemneuro.9b00691","volume":"11","author":"Mohamadpour H.","year":"2020","unstructured":"Mohamadpour H.; Azadi A.; Rostamizadeh K.; Andalib S.; Saghatchi Zanjani M.R.; Hamidi M.; Preparation, optimization, and evaluation of methoxy poly(ethylene glycol)-co-poly(&#x3B5;-caprolactone) nanoparticles loaded by rivastigmine for brain delivery. ACS Chem Neurosci 2020,11(5),783-795","journal-title":"ACS Chem Neurosci"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12951-018-0356-z","volume":"16","author":"S\u00e1nchez-L\u00f3pez E.","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez E.; Ettcheto M.; Egea M.A.; Espina M.; Cano A.; Calpena A.C.; Camins A.; Carmona N.; Silva A.M.; Souto E.B.; Garc\u00eda M.L.; Memantine loaded plga pegylated nanoparticles for alzheimer\u2019s disease: in vitro and in vivo characterization. J Nanobiotechnology 2018,16(1),32","journal-title":"J Nanobiotechnology"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.nano.2009.04.001","volume":"6","author":"Wilson B.","year":"2010","unstructured":"Wilson B.; Samanta M.K.; Santhi K.; Kumar K.P.; Ramasamy M.; Suresh B.; Chitosan nanoparticles as a new delivery system for the anti-alzheimer drug tacrine. Nanomedicine 2010,6(1),144-152","journal-title":"Nanomedicine"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejpb.2008.03.009","volume":"70","author":"Wilson B.","year":"2008","unstructured":"Wilson B.; Samanta M.K.; Santhi K.; Kumar K.P.; Paramakrishnan N.; Suresh B.; Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008,70(1),75-84","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ejps.2011.10.002","volume":"44","author":"Luppi B.","year":"2011","unstructured":"Luppi B.; Bigucci F.; Corace G.; Delucca A.; Cerchiara T.; Sorrenti M.; Catenacci L.; Di Pietra A.M.; Zecchi V.; Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-alzheimer drug tacrine. Eur J Pharm Sci 2011,44(4),559-565","journal-title":"Eur J Pharm Sci"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201818666210910162750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/196390\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201818666210910162750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:15:53Z","timestamp":1668856553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/196390\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201818666210910162750","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}